Clinical Trial Update: CHART-C3G/CLNP023B12011

View source ↗

Summary

Novartis' CHART-C3G trial is evaluating iptacopan (LNP023) for C3 glomerulopathy; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• C3 Glomerulopathy

Drugs mentioned

• iptacopan (iptacopan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: C3 Glomerulopathy, Complement-mediated Kidney Disease | Status: NOT_YET_RECRUITING